Trial · NCT03092674
Adverse events579
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 579
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Azacitidine | 13 | 25 | |
| other | Anemia | Blood and lymphatic system disorders | Azacitidine + Nivolumab | 12 | 25 | |
| other | Anemia | Blood and lymphatic system disorders | Azacitidine +Midostaurin | 13 | 23 | |
| other | Blood and lymphatic system disorders-Other | Blood and lymphatic system disorders | Azacitidine | 1 | 25 | |
| other | Blood and lymphatic system disorders-Other | Blood and lymphatic system disorders | Azacitidine + Nivolumab | 2 | 25 | |
| other | Blood and lymphatic system disorders-Other | Blood and lymphatic system disorders | Azacitidine +Midostaurin | 2 | 23 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Azacitidine | 7 | 25 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Azacitidine + Nivolumab | 3 | 25 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Azacitidine +Midostaurin | 6 | 23 | |
| other | Cardiac disorders-Other | Cardiac disorders | Azacitidine | 1 | 25 | |
| other | Cardiac disorders-Other | Cardiac disorders | Azacitidine + Nivolumab | 1 | 25 | |
| other | Cardiac disorders-Other | Cardiac disorders | Azacitidine +Midostaurin | 3 | 23 | |
| other | Heart failure | Cardiac disorders | Azacitidine | 2 | 25 | |
| other | Heart failure | Cardiac disorders | Azacitidine + Nivolumab | 0 | 25 | |
| other | Heart failure | Cardiac disorders | Azacitidine +Midostaurin | 0 | 23 | |
| other | Myocardial infarction | Cardiac disorders | Azacitidine | 2 | 25 | |
| other | Myocardial infarction | Cardiac disorders | Azacitidine + Nivolumab | 0 | 25 | |
| other | Myocardial infarction | Cardiac disorders | Azacitidine +Midostaurin | 0 | 23 | |
| other | Sinus tachycardia | Cardiac disorders | Azacitidine | 3 | 25 | |
| other | Sinus tachycardia | Cardiac disorders | Azacitidine + Nivolumab | 1 | 25 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03092674/events